Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 14;15(2):513.
doi: 10.3390/cancers15020513.

Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

Alexandre Lugat  1   2   3 , Éric Frampas  2   4 , Yann Touchefeu  2   5 , Éric Mirallié  6 , Maëlle Le Bras  7 , Hélène Senellart  8 , Aurore Rauscher  9 , Vincent Fleury  10 , Loïc Campion  2   11 , Vincent Rohmer  12 , Olivier-François Couturier  13 , Rachida Lebtahi  14 , François Rouzet  15   16 , Philippe Ruszniewski  17   18 , Françoise Kraeber-Bodéré  2   3 , Mickaël Bourgeois  2   3   19 , Catherine Ansquer  2   3
Affiliations

Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

Alexandre Lugat et al. Cancers (Basel). .

Abstract

The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs.

Keywords: 68Ga-DOTANOC; CT scan; MRI; neuroendocrine tumors; somatostatin receptor scintigraphy.

PubMed Disclaimer

Conflict of interest statement

Catherine Ansquer and Rachida Lebtahi reports grants and nonfinancial support from Advanced Accelerator Applications, a Novartis company, François Rouzet from Siemens Healthineers and Spectrum Dynamics. The other authors have nothing to declare.

Figures

Figure 1
Figure 1
Additional lesions detected by 68Ga-DOTANOC (upper: fusion pET and CT images; lower: CT scan). (A) Primary lesion: grade 2 duodenal gastrinoma in a 35-year-old female. (B) Bone metastasis in a 50-year-old female with a grade 1 intestinal NET. (C) Peritoneal carcinomatosis in a 79-year-old female with a grade 2 intestinal NET.
See this image and copyright information in PMC

References

    1. Modlin I.M., Champaneria M.C., Bornschein J., Kidd M. Evolution of the Diffuse Neuroendocrine System–Clear Cells and Cloudy Origins. Neuroendocrinology. 2006;84:69–82. doi: 10.1159/000096997. - DOI - PubMed
    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Volante M., Rosas R., Allìa E., Granata R., Baragli A., Muccioli G., Papotti M. Somatostatin, Cortistatin and Their Receptors in Tumours. Mol. Cell. Endocrinol. 2008;286:219–229. doi: 10.1016/j.mce.2007.12.002. - DOI - PubMed
    1. Reubi J.C., Laissue J., Krenning E., Lamberts S.W. Somatostatin Receptors in Human Cancer: Incidence, Characteristics, Functional Correlates and Clinical Implications. J. Steroid Biochem. Mol. Biol. 1992;43:27–35. doi: 10.1016/0960-0760(92)90184-K. - DOI - PubMed
    1. Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., Lameris J.S., Reubi J.C., Lamberts S.W. Localisation of Endocrine-Related Tumours with Radioiodinated Analogue of Somatostatin. Lancet. 1989;1:242–244. doi: 10.1016/S0140-6736(89)91258-0. - DOI - PubMed

LinkOut - more resources